Estrogen Receptor and Breast Cancer

Celebrating the 60th Anniversary of the Discovery of ER

  • Xiaoting Zhang

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Kenneth S. Korach, Sylvia C. Hewitt, Katherine J. Hamilton, Yin Li, J. Tyler Ramsey, Marleny Garcia et al.
    Pages 15-47
  3. Gregory Bick, Dan Zhao, Xiaoting Zhang
    Pages 49-70
  4. Ping Yi, Zhao Wang, Bert W. O’Malley
    Pages 71-93
  5. Nicholas Pulliam, Jessica Tang, Kenneth P. Nephew
    Pages 129-150
  6. Balkees Abderrahman, V. Craig Jordan
    Pages 151-188
  7. Tomas Reinert, Ryoichi Matsunuma, Airi Han, Matthew J. Ellis
    Pages 215-240
  8. Ian Mitchelle S. de Vera, Udayanga S. Wanninayake, Thomas P. Burris
    Pages 241-263
  9. Xiaoyong Fu, Carmine De Angelis, Jamunarani Veeraraghavan, C. Kent Osborne, Rachel Schiff
    Pages 265-307
  10. Christoforos Thomas, Jan-Åke Gustafsson
    Pages 309-342
  11. Marissa Leonard, Juan Tan, Yongguang Yang, Mahmoud Charif, Elyse E. Lower, Xiaoting Zhang
    Pages 379-403
  12. Back Matter
    Pages 405-417

About this book


The discovery of ER by Dr. Elwood Jensen exactly 60 years ago has not only led to the birth of a whole new vital nuclear receptor research field but also made a rapid, direct and lasting impact on the treatment and prevention of breast cancer. Since that landmark discovery, tremendous progress has been made in our understanding of the molecular functions of ER and development of targeted therapies against ER pathways for breast cancer treatment. However, there is currently no book available addressing these discoveries and recent advancement in a historical and systematic fashion. This book is intended to provide comprehensive, most up-to-date information on the history and recent advancement of ER and breast cancer by world renowned leaders in the field. These chapters include the history of the discovery of ER; physiological and pathological roles of ER; recent discovery of ER cistrome, transcriptome and its regulation of noncoding RNAs such as microRNAs and enhancer RNAs in breast cancer; development and clinical practices of the first targeted therapy Tamoxifen and other antiestrogens for breast cancer treatment; structural basis of ER and antiestrogen actions; molecular insights into endocrine resistance; the role of ER mutants, ER-beta and environmental estrogens in breast cancer; and emerging state-of-the-art therapeutic approaches currently in development to overcome treatment resistance and future perspectives. The book will provide undergraduate and graduate students, basic scientists and clinical cancer researchers, residents, fellows, as well as clinicians, oncology educators and the general public a thorough and authoritative review of these exciting topics.


estrogen receptor breast cancer targeted therapies against ER pathways Tamoxifen molecular functions of ER

Editors and affiliations

  • Xiaoting Zhang
    • 1
  1. 1.Department of Cancer Biology, Vontz Center for Molecular StudiesUniversity of Cincinnati College of MedicineCincinnatiUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Nature Switzerland AG 2019
  • Publisher Name Humana Press, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-99349-2
  • Online ISBN 978-3-319-99350-8
  • Series Print ISSN 2196-9906
  • Series Online ISSN 2196-9914
  • Buy this book on publisher's site